Philip A. Thompson

ORCID: 0000-0003-2086-6031

Also affiliated with Peter MacCallum Cancer Centre

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 20 papers. Top paper: “10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial”.

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30210-6

N/A

6.4DataRank · unranked

334 citations

Abhishek Maiti, Caitlin R. Rausch, Naveen Pemmaraju, Kiran Naqvi, Naval Daver +34 more

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

New England Journal of Medicine(2020)10.1056/nejmoa1910607

N/A

5.4DataRank · unranked

2164 citations

David Marín, Pinaki P. Banerjee, Homer A. Macapinlac, Philip A. Thompson, Rafet Başar +22 more

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Blood Advances(2021)10.1182/bloodadvances.2020003717

N/A

3.2DataRank · unranked

82 citations

Courtney D. DiNardo, Sa A. Wang, Jeffrey L. Jorgensen, Tapan M. Kadia, Naval Daver +28 more

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens

Haematologica(2020)10.3324/haematol.2020.252569

N/A

0.776DataRank · unranked

176 citations

Caitlin R. Rausch, Jörge E. Cortes, Naveen Pemmaraju, Naval Daver, Farhad Ravandi +30 more

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

Blood Cancer Journal(2021)10.1038/s41408-021-00410-w

N/A

0.728DataRank · unranked

127 citations

Courtney D. DiNardo, Naval Daver, Caitlin R. Rausch, Farhad Ravandi, Tapan M. Kadia +20 more

Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality

American Journal of Hematology(2020)10.1002/ajh.26061

N/A

0.697DataRank · unranked

103 citations

Wei Qiao, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Elias Jabbour +26 more

Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome

Blood(2022)10.1182/blood.2021011386

N/A

0.650DataRank · unranked

75 citations

Kerry A. Rogers, Svitlana Tyekucheva, Zixu Wang, Samantha Pazienza, Sarah K. Renner +10 more

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

Blood Advances(2023)10.1182/bloodadvances.2022009391

N/A

0.510DataRank · unranked

29 citations

Tapan M. Kadia, Nicholas J. Short, Gautam Borthakur, Sa A. Wang, Wei Wang +22 more

International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations

Blood(2025)10.1182/blood.2024028064

N/A

0.425DataRank · unranked

16 citations

Monia Marchetti, Othman Al‐Sawaf, Ohad Benjamini, Alexey V. Danilov, Matthew S. Davids +24 more

Artificial Intelligence Assessment of Chest Radiographs for COVID-19

Clinical Lymphoma Myeloma & Leukemia(2024)10.1016/j.clml.2024.11.013

N/A

0.165DataRank · unranked

2 citations

Guillermo Garcia‐Manero, Masayuki Nigo, Elias Jabbour, Farhad Ravandi, William G. Wierda +14 more

Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression

Blood Cancer Journal(2025)10.1038/s41408-025-01382-x

N/A

0.165DataRank · unranked

2 citations

Burcu Aslan, Ganiraju C. Manyam, LaKesla R. Iles, Natalia Timofeeva, Neetu Singh +8 more

Advances in the Understanding of Richter Transformation

Hematology/Oncology Clinics of North America(2025)10.1016/j.hoc.2025.05.011

N/A

0.104DataRank · unranked

1 citations

Erin M. Parry, Philip A. Thompson

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Blood(2024)10.1182/blood-2024-211110

N/A

0DataRank · unranked

2 citations

Philip A. Thompson, Jan A. Burger, Musa Yılmaz, Nitin B. Jain, Tapan M. Kadia +23 more

Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL

Blood Cancer Journal(2025)10.1038/s41408-025-01236-6

N/A

0DataRank · unranked

12 citations

Ying Huang, Sarah Miller, John N. Allan, Seema A. Bhat, David A. Bond +40 more

STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells

Oncotarget(2021)10.18632/oncotarget.27884

N/A

0DataRank · unranked

11 citations

David Harris, Ping Li, Zhiming Liu, Preetesh Jain, Taghi Manshouri +10 more

Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations

Blood(2021)10.1182/blood.2021012315

N/A

0DataRank · unranked

24 citations

Ekaterina Kim, William G. Wierda, Alessandra Ferrajoli, Nitin Jain, Philip A. Thompson +4 more

Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia

Blood Cancer Journal(2022)10.1038/s41408-022-00760-z

N/A

0DataRank · unranked

23 citations

Robert J. Kreitman, Enrico Tiacci, Leslie A. Andritsos, Versha Banerji, Jacqueline C. Barrientos +40 more

TP53‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis

American Journal of Hematology(2022)10.1002/ajh.26595

N/A

0DataRank · unranked

14 citations

Raamis Khwaja, Rashmi Kanagal‐Shamanna, Guilin Tang, Jan A. Burger, Philip A. Thompson +10 more

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Blood(2023)10.1182/blood-2023-188084

N/A

0DataRank · unranked

1 citations

Philip A. Thompson, Akhil Jain, Jan A. Burger, Alessandra Ferrajoli, Jayastu Senapati +27 more

Incidence and Management of COVID-19 Infections in Vaccinated Patients with CLL

Blood(2023)10.1182/blood-2023-173992

N/A

0DataRank · unranked

0 citations

Ted Gooley, Tanya Siddiqi, Deborah M. Stephens, Catherine M. Broome, Stephen E. Spurgeon +18 more